Sarepta Therapeutics (SRPT) Tops Q3 EPS by 54c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.80), $0.54 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $230.27 million versus the consensus estimate of $233.93 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in
• BMO starts chip stocks coverage: Here are its preferred picks